In the present study, we conducted a head-to-head comparison of plasma p-tau217 and tau-PET in amyloid-positive patients with MCI or mild dementia due to AD to assess these biomarkers’ relations with each other and with demographic, clinical, and other neuroimaging measures. The gene discussed is MAPT; the disease is amyloidosis.